Comparative efficacy of biological agents in methotrexate- refractory rheumatoid arthritis patients: a Bayesian mixed treatment comparison

키워드

참고문헌 (39)

1. Schmitz S, "A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach", Ann Rheum Dis, 71, pp.225~230 (2012)
2. Devine EB, "Effectiveness of biologic therapies for rheumatoid arthritis:an indirect comparisons approach", Pharmacotherapy, 31, pp.39~51 (2011)
3. Gallego-Galisteo M, "Indirect comparison of biological treatments in refractory rheumatoid arthritis", J Clin Pharm Ther, 37, pp.301~307 (2012)
4. Singh JA, "Summary of AHRQ’s comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults: an update", J Manag Care Pharm, 18(4 Supp C), pp.S1~S18 (2012)
5. Golicki D, "Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials", Pol Arch Med Wewn, 122, pp.22~32 (2012)
6. Ahn J, "Bayesian Meta-Analysis Method" (2014), National Evidence-based Healthcare Collaborating Agency
7. Higgins JP, "Cochrane Handbook for Systematic Reviews of Interventions" (2008), Wiley-Blackwell
8. Whitlock EP, "Using existing systematic reviews in complex systematic reviews", Ann Intern Med, 148, pp.776~782 (2008)
9. Aaltonen KJ, "Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis", PLoS One, 7, pp.e30275~ (2012)
10. Gaujoux-Viala C, "Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis", Ann Rheum Dis, 69, pp.1004~1009 (2010)
11. Turkstra E, "A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis", Curr Med Res Opin, 27, pp.1885~1897 (2011)
12. Graudal N, "Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis:meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons", Arthritis Rheum, 62, pp.2852~2863 (2010)
13. Genovese MC, "Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study", J Rheumatol, 39, pp.1185~1191 (2012)
14. Huang J, "Infliximab reduces CD147, MMP-3, and MMP-9 expression in peripheral blood monocytes in patients with active rheumatoid arthritis", Eur J Pharmacol, 698, pp.429~434 (2013)
15. Jobanputra P, "A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis:a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years", BMJ Open, 2, pp.e001395~ (2012)
16. 주고운, "Safety and Efficacy Evaluation for the Addition of Either Etanercept or Leflunomide in Korean Rheumatoid Arthritis Patients Inadequately Responding to Methotrexate", 대한류마티스학회지, 20(3), pp.166~171 (2013), 대한류마티스학회
17. Kameda H, "Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial", Mod Rheumatol, 20, pp.531~538 (2010)
18. Kay J, "Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study", Arthritis Rheum, 58, pp.964~975 (2008)
19. Keystone E, "Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study", Arthritis Rheum, 58, pp.3319~3329 (2008)
20. Keystone EC, "Golimumab, a human antibody to tumour necrosis factor {alpha}given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study", Ann Rheum Dis, 68, pp.789~796 (2009)
21. Keystone EC, "Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial", Arthritis Rheum, 50, pp.353~363 (2004)
22. Schiff M, "Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate", Ann Rheum Dis, 67, pp.1096~1103 (2008)
23. Strand V, "Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial", Arthritis Res Ther, 11, pp.R170~ (2009)
24. Strand V, "Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial", Ann Rheum Dis, 70, pp.996~1002 (2011)
25. van Vollenhoven RF, "Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial", Lancet, 374, pp.459~466 (2009)
26. Weinblatt ME, "Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial", Ann Rheum Dis, 72, pp.381~389 (2013)
27. Weinblatt ME, "Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial", Arthritis Rheum, 48, pp.35~45 (2003)
28. Wong M, "Infliximab improves vascular stiffness in patients with rheumatoid arthritis", Ann Rheum Dis, 68, pp.1277~1284 (2009)
29. "Clinical and economic overview:biological response modifier agents for adults with rheumatoid arthritis" (2010)[URL]
30. Graudal N, "Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials", PLoS One, 9, pp.e106408~ (2014)
31. Baji P, "Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison", Eur J Health Econ, 15(Suppl 1), pp.S53~S64 (2014)
32. Singh JA, "A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview", CMAJ, 181, pp.787~796 (2009)
33. Launois R, "Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis", J Rheumatol, 38, pp.835~845 (2011)
34. Nesbitt A, "Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents", Inflamm Bowel Dis, 13, pp.1323~1332 (2007)
35. Nesbitt A, "Effect of structure of conventional anti-TNFs and certolizumab pegol on mode of action in rheuma toid arthritis", Ann Rheum Dis, 66(Suppl 2), pp.296~ (2007)
36. Goekoop-Ruiterman YP, "Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial", Arthritis Rheum, 52, pp.3381~3390 (2005)
37. Messori A, "Biological drugs for the treatment of rheumatoid arthritis by the subcutaneous route: interpreting efficacy data to assess statistical equivalence", Ther Adv Musculoskelet Dis, 6, pp.207~216 (2014)
38. Jansen JP, "Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1", Value Health, 14, pp.417~428 (2011)
39. Ades AE, "Indirect and mixed treatment comparisons in arthritis research", Rheumatology (Oxford), 50(Suppl 4), pp.i5~i9 (2011)

관련 논문AI추천